Teladoc Health (NYSE: TDOC) was once a celebrated pandemic-era success story, with its revenue and stock price reaching remarkable highs during that period.
The telemedicine specialist has been unable to sustain that momentum, and over the past five years the stock has lost more than 90% of its value.
In its most recent quarterly update, Teladoc reported revenue of $613.8 million, a 2% decline year over year.
The company posted a net loss per share of $0.36 for the quarter, an improvement from the loss per share of $0.53 recorded in the year-ago period.
A significant goodwill impairment charge weighed on the bottom line in the first quarter of 2025, and the company remains unprofitable with no clear path to organic improvement.
Teladoc’s BetterHelp virtual therapy segment, once a key growth driver, saw both revenue and paying users fall 9% year over year during the period.
A relative bright spot was the company’s international business, where revenue jumped 17% year over year to $122.3 million.
Teladoc faces mounting competition from new market entrants as well as established medical networks that have built their own virtual health platforms, while the return to in-person care has presented an additional challenge.
Turning $50,000 into $1 million in a decade requires a compound annual growth rate of 35%, and even starting with $100,000 would still demand a CAGR of 26%.
Teladoc has taken some steps toward recovery, including expanding BetterHelp’s insurance coverage in select states, with the company estimating an annualized run rate of $75 million for insurance-covered sessions and targeting at least $125 million by year end.
The company is also leaning on artificial intelligence, with plans to introduce a range of AI products and tools on its platform to boost revenue.
International expansion continues, though varying regulatory frameworks across healthcare markets and uneven coverage could require significant time and financial investment to make the segment a meaningful profit driver.
Insurance coverage for BetterHelp addresses one headwind but does not eliminate competition, some of which also carries insurance, limiting the initiative’s overall impact.
Teladoc’s consistent net losses and its track record over recent years make a high-growth recovery scenario difficult to rely upon, and its AI-powered tools, while potentially promising, remain unproven.
The company’s future remains highly uncertain, and it is not clear that Teladoc can stop the bleeding anytime soon, let alone perform well enough to make investors millionaires by 2036.
